Loading
Cancer Risks and Factors / Metabolism, Diabetes, and Cancer / Cancer, Hypoxia, and Metabolism · Journal article
World Journal of Translational Medicine · August 10, 2026
Raises a question worth testing. It does not answer one.
This is a perspective article that proposes a mechanistic hypothesis linking insulin resistance, DPP4 inhibition, and mitochondrial dysfunction in cancer patients, but presents no primary empirical evidence, clinical trial data, or quantitative outcomes to support or test the hypothesis. The article reviews existing literature and outlines a conceptual framework for future investigation rather than reporting original research findings.
Journal article. Patients with cancer comorbid with insulin resistance or type 2 diabetes; theoretical application to obesity.
Literature supports the proposal that cancer patients with insulin resistance have less active mitochondria in platelets than cancer patients without insulin resistance or normal individuals Platelet mitochondrial bioenergetic profile may signal early mitochondrial dysfunction in patients with cancer and insulin resistance
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This perspective does not provide evidence sufficient to change clinical practice. It identifies gaps in knowledge and proposes a theoretical framework for future research into the intersection of insulin resistance, DPP4, and cancer-related mitochondrial dysfunction.
A perspective article proposing mechanistic relationships between insulin resistance, DPP4, and mitochondrial dysfunction in cancer, without presenting primary empirical data or clinical trials to test the hypothesis.
This perspective does not provide evidence sufficient to change clinical practice. It identifies gaps in knowledge and proposes a theoretical framework for future research into the intersection of insulin resistance, DPP4, and cancer-related mitochondrial dysfunction.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Insulin resistance, a pathophysiological response in metabolic syndrome, raises cancer risk.Mitochondrial dysfunction is a hallmark of all cancers.The mitochondrial energetic profile of platelets of cancer patients with insulin resistance is unclear.Similarly, the profile of mitochondrial dysfunction in type 2 diabetes (T2-D) has not yet been published.The transmembrane protein in human adipose tissue, known as dipeptidyl peptidase 4 (DPP4), is associated with T2-D secondary to obesity.Furthermore, DPP4 has been implicated in cancer pathogenesis.Studies have shown a connection between obesity and cancer.However, whether DPP4 inhibition ameliorates insulin resistance in cancer patients has not been elucidated.This perspective aims to: (1) Explore how platelet mitochondria fail in cancer patients with insulin resistance; (2) Discuss how blocking DPP4 might antagonize insulin resistance in cancer; and (3) Describe a cell culture model for obesity and insulin resistance.The available literature supports the proposal that patients with cancer and insulin resistance (or T2-D) have less active mitochondria in their platelets than patients with cancer without insulin resistance or normal individuals.The platelet mitochondrial bioenergetic profile may signal early mitochondrial dysfunction in patients with cancer and insulin resistance.The proposed model is amenable to patients with T2-D, obesity.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.